Rapid progress towards improved diagnostics and effective therapies for human glioma requires access to a reliable, extensive and well described source of tumor tissue, backed up by all relevant clinical data. We have established and maintained a tissue biorepository for brain tumors at our center since 1992. It currently contains over 1,300 eases, each represented by specimens in several states: snap-frozen samples collected in the operating room, viable primary explant cultures, normal and tumor genomic DNA and paraffin-embedded multiple directed biopsies are routinely collected, and all amenable to different modes of analysis, making a wide range of studies possible. Analysis of specimens from this biorepository has already resulted in 54 publications and 62 published abstracts. In addition to the tissue, and of equal importance, is the description of the clinical population. This has been achieved to date by documentation of the proceedings of our neuro-oncology tumor board, and resulted in the collection of clinical demographics and outcomes, responses to therapy, time-to-tumor-progression and overall survival data. Here we propose to expand and maintain this biorepository as our surgical case load increases, and extend its use by analyzing samples with new high throughput molecular technologies, while also developing the information tools to allow the correlation of research and clinical data. Efforts are underway to apply high throughput genomic technology to all the glioma samples in our biorepository, initially by performing LOH analysis at 12 discrete loci known to be important in gliomagenesis and progression. Importantly our biorepository has also been selected as the tissue source for the NCI Brain Tumor Genome Anatomy Project's comprehensive eDNA microarray analysis of gene expression. The application of these methodologies will allow the identification of clinically relevant sub-types of glioma on a molecular basis. Successful completion of this work will result in a biorepository containing glioma samples that are comprehensively characterized at the molecular and clinical level, and for which ample material remains for exploitation with new analysis modalities, such as proteomics. We seek support to expand this multi-use glioma biorepository into an ongoing resource of the best characterized glioma material with clinical correlative and genomic data available.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects (R24)
Project #
5R24CA095809-04
Application #
6873018
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J2))
Program Officer
Lively, Tracy (LUGO)
Project Start
2002-04-01
Project End
2007-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
4
Fiscal Year
2005
Total Cost
$182,292
Indirect Cost
Name
Henry Ford Health System
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202
Golembieski, William A; Thomas, Stacey L; Schultz, Chad R et al. (2008) HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion. Glia 56:1061-75
Jiang, Wei; Cazacu, Simona; Xiang, Cunli et al. (2008) FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia 10:235-43
Jiang, Wei; Xiang, Cunli; Cazacu, Simona et al. (2008) Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration. Neoplasia 10:1335-42
Hu, B; Guo, P; Bar-Joseph, I et al. (2007) Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26:5577-86
Xiang, Cunli; Sarid, Ronit; Cazacu, Simona et al. (2007) Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells. Biochem Biophys Res Commun 362:612-8
Okamoto, Hiroaki; Li, Jie; Glasker, Sven et al. (2007) Proteomic comparison of oligodendrogliomas with and without 1pLOH. Cancer Biol Ther 6:391-6
Kotliarov, Yuri; Steed, Mary Ellen; Christopher, Neil et al. (2006) High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res 66:9428-36
Sarris, A H; Phan, A; Goy, A et al. (2002) Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park) 16:27-31